Erratum to: Comparative In Vivo Evaluations of Curcumin and Its Analog Difluorinated Curcumin Against Cisplatin-Induced Nephrotoxicity [Biol Trace Elem Res, (2014), 157, 156–163 , 10.1007/s12011-014-9886-x];Comparative in vivo evaluations of curcumin and its analog difluorinated curcumin against cisplatin-induced nephrotoxicity

Biological Trace Element Research

Volumn 157, Issue 2, 2014, Pages 156-163

  Sahin, Kazim ^a   Orhan, Cemal ^a   Tuzcu, Mehmet ^a   Muqbil, Irfana ^b   Sahin, Nurhan ^a   Gencoglu, Hasan ^a   Guler, Osman ^c   Padhye, Subhash B ^d   Sarkar, Fazlul H ^e   Mohammad, Ramzi M ^e  

^a FIRAT UNIVERSITY   (Turkey)

^b ALIGARH MUSLIM UNIVERSITY   (India)

^c Vet Control and Research Institute   (Turkey)

^d UNIVERSITY OF PUNE   (India)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CDF; Cisplatin; Curcumin; Nephrotoxicity

Indexed keywords

8 ISOPROSTANE; CISPLATIN; CREATININE; CURCUMIN; CURCUMIN DIFLUORINATED; CYCLOOXYGENASE 2; HEME OXYGENASE 1; INITIATION FACTOR 4E BINDING PROTEIN 1; MALONALDEHYDE; MAMMALIAN TARGET OF RAPAMYCIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PROTEIN KINASE B; S6 KINASE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; IN VIVO STUDY; LIVER PROTECTION; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; UREA BLOOD LEVEL;

RATTUS; RATTUS NORVEGICUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; CISPLATIN; CREATININE; CURCUMIN; HYDROCARBONS, FLUORINATED; KIDNEY; KIDNEY DISEASES; LIPID PEROXIDATION; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 84895141381     PISSN: 01634984     EISSN: 15590720     Source Type: Journal    
DOI: 10.1007/s12011-014-0198-y     Document Type: Erratum

References (54)

1. Rosenberg B, VanCamp L, Trosko JE et al (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222:385-386
2. Loehrer PJ, Einhorn LH (1984) Drugs five years later. Cisplatin. Ann Intern Med 100:704-713
3. Ali BH, Al Moundhri MS (2006) Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 44:1173-1183
4. Saha S, Adhikary A, Bhattacharyya P et al (2012) Death by design: where curcumin sensitizes drug-resistant tumours. Anticancer Res 32:2567-2584
5. Mendonça LM, da Silva Machado C, Teixeira CC et al (2013) Curcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells. Neurotoxicology 34:205-211
6. Goel A, Aggarwal BB (2010) Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62:919-930
7. Dhillon N, Aggarwal BB, Newman RA et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491-4499
8. Kanai M, Yoshimura K, Asada M et al (2010) A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68:157-1649
9. Bar-Sela G, Epelbaum R, Schaffer M (2010) Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 17:190-197
10. Cen L, Hutzen B, Ball S et al (2009) New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells. BMC Cancer 9:99
11. Padhye S, Banerjee S, Chavan D et al (2009) Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res 26:2438-2445
12. Ali S, Ahmad A, Banerjee S et al (2010) Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70:3606-3617
13. Dandawate PR, Vyas A, Ahmad A et al (2012) Inclusion complex of novel curcumin analogue CDF and β-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Pharm Res 29:1775-1786
14. Azmi AS, Ali S, Banerjee S et al (2011) Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Am J Transl Res 3:374-382
15. Bao B, Ali S, Kong D et al (2011) Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. Plos One 6, E17850
16. Kanwar SS, Yu Y, Nautiyal J et al (2011) Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 28:827-838
17. Dandawate P, Khan E, Padhye S et al (2012) Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells. Bioorg Med Chem Lett 22:3104-3108
18. Li Y, Kong D, Wang Z et al (2011) Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. Cancer Prev Res (Phila) 4:1495-1506
19. Bao B, Ali S, Banerjee S et al (2012) Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72:335-345
20. Ulu R, Dogukan A, Tuzcu M et al (2012) Regulation of renal organic anion and cation transporters by thymoquinone in cisplatin induced kidney injury. Food Chem Toxicol 50:1675-1679
21. Karatepe M (2004) Simultaneous determination of ascorbic acid and free malondialdehyde in human serum by HPLC/UV. LC-GC North Am 22:362-365
22. Wong YT, Ruan R, Tay FE (2006) Relationship between levels of oxidative DNA damage, lipid peroxidation and mitochondrial membrane potential in young and old F344 rats. Free Radic Res 40:393-402
23. Banerjee S, Kaseb AO, Wang Z et al (2009) Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69:5575-5583
24. Azmi AS, Philip PA, Beck FW et al (2011) MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene 30:117-126
25. Piccart MJ, Lamb H, Vermorken JB (2001) Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 12:1195-1203
26. Surendiran A, Balamurugan N, Gunaseelan K et al (2010) Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: an evaluative study. Indian J Pharmacol 42:40-43
27. Hanigan MH, Devarajan P (2003) Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1:47-61
28. Alaikov T, Konstantinov SM, Tzanova T et al (2007) Antineoplastic and anticlastogenic properties of curcumin. Ann N Y Acad Sci 1095:355-370
29. Antunes LMG, Darin JDC, Bianchi NLP (2001) Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res 43:145-150
30. Antunes LMG, Araújo MC, Darin JD et al (2000) Effects of the antioxidants curcumin and vitamin C on cisplatin-induced clastogenesis in Wistar rat bone marrow cells. Mutat Res 465:131-137
31. Kuhad A, Pilkhwal S, Sharma S et al (2007) Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem 55:10150-10155
32. Ilbey YO, Ozbek E, Cekmen M et al (2009) Protective effect of curcumin in cisplatin-induced oxidative injury in rat testis: mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways. Hum Reprod 24:1717-1725
33. Mendonça LM, dos Santos GC, dos Santos RA et al (2010) Evaluation of curcumin and cisplatin-induced DNA damage in PC12 cells by the alkaline comet assay. Hum Exp Toxicol 29:635-643
34. Anand P, Kunnumakkara AB, Newman RA et al (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807-818
35. Kim SH, Hong KO, Chung WY et al (2004) Abrogation of cisplatin-induced hepatotoxicity in mice by xanthorrhizol is related to its effect on the regulation of gene transcription. Toxicol Appl Pharmacol 196:346-355
36. Banning A, Brigelius-Flohé R (2005) NF-kappaB, Nrf2, and HO-1 interplay in redox-regulated VCAM-1 expression. Antioxid Redox Signal 7:889-899
37. Trujillo J, Chirino YI, Molina-Jijón E et al (2013) Renoprotective effect of the antioxidant curcumin: recent findings. Redox Biol 17:448-456
38. Soetikno V, Sari FR, Lakshmanan AP et al (2013) Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway. Mol Nutr Food Res 57:1649-1659
39. Ramadoss J, Stewart RH, Cudd TA (2011) Acute renal response to rapid onset respiratory acidosis. Can J Physiol Pharmacol 89:227-231
40. Pritchard JB, Miller DS (1996) Renal secretion of organic anions and cations. Kidney Int 49:1649-1654
41. Srimaroeng C, Perry JL, Pritchard JB (2008) Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica 38:889-935
42. Ciarimboli G (2008) Organic cation transporters. Xenobiotica 38:936-971
43. Aleksunes LM, Augustine LM, Scheffer GL et al (2008) Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology 250:82-88
44. Tirkey N, Kaur G, Vij G et al (2005) Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol 5:15
45. Cole SP, Sparks KE, Fraser K et al (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910
46. Altenberg GA (2004) Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily. Curr Med Chem Anticancer Agents 4:53-62
47. Reid G, Wielinga P, Zelcer N et al (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 100:9244-9249
48. Reid G, Wielinga P, Zelcer N et al (2003) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63:1094-1103
49. Wortelboer HM, Usta M, van der Velde AE et al (2003) Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol 16:1642-1651
50. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274-293
51. Laplante M, Sabatini DM (2012) mTOR Signaling. Cold Spring Harb Perspect Biol 4:1-3
52. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22
53. Johnson SM, Gulhati P, Rampy BA et al (2010) Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 210:767-778
54. Johnson SM, Gulhati P, Arrieta I (2009) Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res 29:3185-3190